Fundamental Analysis of Kiora Pharmaceuticals Inc - Growth / Value Index
KPRX - Valuation Highlights
Valuation Analysis
Tsr Value Index - Good Score of 65.62
Price to Earning Ratio is 3.33 and EV to EBITDA is 4.78 suggesting company is undervalued.
Price to Book Ratio is 0.519 indicating that it is undervalued.
Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Price to Earning | 2.88 | -0.187 | -604.79 % | |
Price to Book | 0.449 | 0.391 | 1134.58 % | 0.495 |
Price to Sales | 0.402 | 0 | 0 % | |
Enterprise Value to EBITDA Multiple | 4.01 | 0.0016 | -99.61 % |
KPRX - Profitability Highlights
Profitability Analysis
Earning Yield of 30.07 %
Steady Growth in EPS for last four quarters
Good Return on Equity of 15.61% is achieved by the company
Good Net Margin of 13.98% is achieved by the company
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Return On Equity | 15.61 | -208.58 | -75.17 % | 38.54 |
Return On Asset | 10.50 | -92.94 | -27.80 % | 31.70 |
Net Profit Margin | 13.98 | 0 | 0 % | 84.08 |
Operating Profit Margin | 14.07 | 0 | 0 % | 82.56 |
EBITDA Margin | 16.12 | 0 | 0 % | 82.66 |
Highlights
Market Cap | 12944.31 K |
Enterprise Value | 10536.69 K |
Price/Book TTM | 0.449 |
Outstanding Share | 26256.20 K |
Float/ Outstanding Share | 50.19% |
Dividend Yield | 0 % |
Share Holding
Guru Numbers
Price/Graham No | 0.223 |
Peter Lynch Ratio | 0 |
Piotroski F Score | 3.00 |
Altman Z Score | -16.78 |
Sloan Ratio | -0.265 |
Peter Lynch Fair Value | 0 |
KPRX - Growth Highlights
Growth Analysis
Quarterly sales in last 5 years is trending up
Annual sales in last 3 years is trending down
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | 16283.87 K | % | 5536.34 % |
Gross Profit | 15876.77 K | 53.42 % | 201534 % |
EBITDA | 2624.63 K | 5.45 % | 766.55 % |
Net Profit | 2276.86 K | 6.18 % | 693.02 % |
EPS | 0.171 | 85.81 % | NA |
KPRX - Stability Highlights
Stability Analysis
Paid More Than 50% of Debt, Heading towards debt free
Debt to equity ratio has decreased and is lowest in last three years
Tsr Stability Index - Poor Score of 29.69
Altman Z Score of -16.62 suggest high risk
Company is unable to generate enough free cash to support the business.
Interest Coverage of -1144.78
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ |
---|---|---|---|
Debt to Equity Ratio | 0.0077 | -16.92 % | 0.0014 |
Cash Ratio | 1.50 | -17.58 % | |
Quick Ratio | 2.90 | 0 % | 21.02 |
Shareholders Equity | 44.56 | -27.04 % | |
Debt to EBITDA | -0.0037 | 52.94 % |
Historical Valuation Ratios of Kiora Pharmaceuticals Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Kiora Pharmaceuticals Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Kiora Pharmaceuticals Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Kiora Pharmaceuticals Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)